A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alector Inc.
• Collaborator: AbbVie

Criteria

Inclusion Criteria:

• Completion of the Planned Treatment Period in the AL002-2 study.

• The participant is willing and able to give informed consent.

• Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week

Exclusion Criteria:

• Participants deemed not able to provide consent or assent by the Investigator or by local regulations.

• Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons.

• Participation deemed inappropriate per Investigator discretion.